All Stories

  1. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens

    Article • Expert Opinion on Drug Metabolism & Toxicology, January 2019, Taylor & Francis

    Dr Irene Galani

  2. Activity of Plazomicin (ACHN-490) against MDR clinical isolates ofKlebsiella pneumoniae, Escherichia coli, andEnterobacterspp. from Athens, Greece

    Article • Journal of Chemotherapy, August 2012, Taylor & Francis

    Dr Irene Galani, Dr George L Daikos